Skip to main content
PharmSpace

Angiotensin receptor blockers · Cardiovascular

Valsartan

Diovan®(brand names vary by market)

The ARB that carries the heart-failure and post-infarct evidence.

Illustration of Valsartan as a tabletVAL

Also: capsule

Mechanism

Blocks the angiotensin II type 1 receptor directly, leaving bradykinin metabolism untouched, which is why the cough does not happen.

Open the interactive pathway

Indications

  • Hypertension
  • Heart failure with reduced ejection fraction
  • Post myocardial infarction with left ventricular dysfunction

Formulations

TabletCapsule

Dosing concepts

Substitution

The usual reason to reach for it is an ACE-inhibitor cough. Angioedema is a different matter: cross-reactivity is low but not zero, and the decision belongs with a specialist.

Heart failure

Target doses in HFrEF are considerably higher than antihypertensive doses, which is a frequent under-treatment trap.

Concepts, not prescribing instructions. Practice numbers live in current references and local protocols.

Pharmacokinetics

Bioavailability
~25%
Half-life
~6 h, with receptor binding outlasting the plasma level
Elimination
hepatic: Mostly biliary; only a small renal fraction
Protein binding
~95%
Play with these concepts in the PK Lab

Adverse effects

  • Hyperkalemiacommon & serious
  • Hypotension and dizzinesscommon
  • Acute kidney injury in the volume-depleteserious
  • AngioedemaseriousMuch rarer than with ACE inhibitors, but described.

Contraindications & precautions

Contraindications

  • Pregnancy
  • Bilateral renal artery stenosis
  • Concurrent aliskiren in diabetes

Precautions

  • Volume depletion
  • Renal impairment
  • Combination with an ACE inhibitor, which is now avoided

Interactions

Monitoring

Potassium and creatinine

Same class effects as an ACE inhibitor, cough aside · 1 to 2 weeks after any change

Blood pressure

Effect

Counselling points

  • Once or twice daily as prescribed.
  • This is the alternative for people who developed a cough on the other type; it should not do the same.
  • Avoid potassium salt substitutes.
  • Stop and tell us if you become pregnant.

Clinical pearls

  • ARBs are not gentler than ACE inhibitors on the kidney or on potassium. The only reliable difference is the cough.
  • Combining an ACE inhibitor with an ARB doubles the adverse events without improving outcomes; that combination was abandoned on evidence, not on theory.

References & review

  • Valsartan product monograph (consult the current version for your market) (monograph)
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed. (reference-work)

Last reviewed 2026-08-16 · jurisdiction: global · drug information changes; verify against current references before practice use.